Hepatitis Monthly

Published by: Kowsar

The Efficacy of 12 Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients with Cirrhosis, Genotypes 1 and 3

Shahin Merat 1 , Amir Houshang Sharifi 1 , Arghavan Haj-Sheykholeslami 1 , Hossein Poustchi 1 , Babak Fattahi 1 , Alireza Nateghi-Baygi 1 , Seyed Moayed Alavian 2 and Reza Malekzadeh 1 , *
Authors Information
1 Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran
2 Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran
Article information
  • Hepatitis Monthly: January 01, 2017, 17 (1); e44564
  • Published Online: December 14, 2016
  • Article Type: Research Article
  • Received: December 6, 2016
  • Accepted: December 13, 2016
  • DOI: 10.5812/hepatmon.44564

To Cite: Merat S, Sharifi A H, Haj-Sheykholeslami A, Poustchi H, Fattahi B, et al. The Efficacy of 12 Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients with Cirrhosis, Genotypes 1 and 3, Hepat Mon. 2017 ; 17(1):e44564. doi: 10.5812/hepatmon.44564.

Abstract
Copyright © 2016, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
Footnotes
References
  • 1. Hatzakis A, Chulanov V, Gadano AC, Bergin C, Ben-Ari Z, Mossong J, et al. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2. J Viral Hepat. 2015; 22 Suppl 1: 26-45[DOI][PubMed]
  • 2. Sibley A, Han KH, Abourached A, Lesmana LA, Makara M, Jafri W, et al. The present and future disease burden of hepatitis C virus infections with today's treatment paradigm - volume 3. J Viral Hepat. 2015; 22 Suppl 4: 21-41[DOI][PubMed]
  • 3. Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, Radmard AR, et al. Seroprevalence of hepatitis C virus: the first population-based study from Iran. Int J Infect Dis. 2010; 14 Suppl 3: 113-6[DOI][PubMed]
  • 4. Liakina V, Hamid S, Tanaka J, Olafsson S, Sharara AI, Alavian SM, et al. Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 3. J Viral Hepat. 2015; 22 Suppl 4: 4-20[DOI][PubMed]
  • 5. Butt AA, Yan P, Shaikh OS, Chung RT, Sherman KE, Erchives study . Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES. Liver Int. 2016; 36(9): 1275-83[DOI][PubMed]
  • 6. Terrault NA, Zeuzem S, Di Bisceglie AM, Lim JK, Pockros PJ, Frazier LM, et al. Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response. Gastroenterology. 2016; 151(6): 1131-1140 e5[DOI][PubMed]
  • 7. Alfaleh FZ, Nugrahini N, Maticic M, Tolmane I, Alzaabi M, Hajarizadeh B, et al. Strategies to manage hepatitis C virus infection disease burden - volume 3. J Viral Hepat. 2015; 22 Suppl 4: 42-65[DOI][PubMed]
  • 8. Butt AA, Yan P, Shaikh OS, Chung RT, Sherman KE, Erchives study . Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES. Liver Int. 2016; 36(5): 651-8[DOI][PubMed]
  • 9. Pol S, Corouge M, Vallet-Pichard A. Daclatasvir-sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life. Hepat Med. 2016; 8: 21-6[DOI][PubMed]
  • 10. Leroy V, Angus P, Bronowicki JP, Dore GJ, Hezode C, Pianko S, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+). Hepatology. 2016; 63(5): 1430-41[DOI][PubMed]
  • 11. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016; 63(5): 1493-505[DOI][PubMed]
  • 12. Feld JJ, Jacobson IM, Sulkowski MS, Poordad F, Tatsch F, Pawlotsky JM. Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection. Liver Int. 2016; [DOI][PubMed]
  • 13. European Association for the Study of the Liver. Electronic address EEE. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2016; [DOI][PubMed]
  • 14. Sharifi AH, Haj-Sheykholeslami A, Poustchi H, Golzari R, Merat S, Malekzadeh R. Efficacy of locally manufactured sofosbuvir and daclatasvir (sovodak) in combination with ribavirin in treating patients with chronic hepatitis c and cirrhosis in iran - preliminary report. Govaresh. 2016; 21(2): 93-7
  • 15. Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015; 61(4): 1127-35[DOI][PubMed]
  • 16. Jabbari H, Bayatian A, Sharifi AH, Zaer-Rezaee H, Fakharzadeh E, Asadi R, et al. Safety and efficacy of locally manufactured pegylated interferon in hepatitis C patients. Arch Iran Med. 2010; 13(4): 306-12[PubMed]
  • 17. Jabbari H, Zamani F, Hatami K, Sheikholeslami A, Fakharzadeh E, Shahzamani K, et al. Pegaferon in hepatitis C: Results of a Multicenter Study. Middle East J Dig Dis. 2011; 3(2): 110-4[PubMed]
  • 18. Gergely AE, Lafarge P, Fouchard-Hubert I, Lunel-Fabiani F. Treatment of ribavirin/interferon-induced anemia with erythropoietin in patients with hepatitis C. Hepatology. 2002; 35(5): 1281-2[DOI][PubMed]
  • 19. Tapper EB, Hughes MS, Buti M, Dufour JF, Flamm S, Firdoos S, et al. The optimal timing of hepatitis C therapy in transplant eligible patients with Child B and C Cirrhosis: A Cost-Effectiveness Analysis. Transplantation. 2016; [DOI][PubMed]
  • 20. Wirth TC, Manns MP. The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma. Ann Oncol. 2016; 27(8): 1467-74[DOI][PubMed]
  • 21. D'Ambrosio R, Della Corte C, Colombo M. Hepatocellular Carcinoma in Patients with a Sustained Response to Anti-Hepatitis C Therapy. Int J Mol Sci. 2015; 16(8): 19698-712[DOI][PubMed]
  • 22. Alavian SM, Hajarizadeh B, Bagheri Lankarani K, Sharafi H, Ebrahimi Daryani N, Merat S, et al. Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline. Hepat Mon. 2016; 16(8): 40959[DOI][PubMed]
  • 23. Alavian SM, Rezaee-Zavareh MS. Daclatasvir-based treatment regimens for hepatitis c virus infection: A systematic review and meta-analysis. Hepat Mon. 2016; 16(9): 41077[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments